Could injecting immunotherapy into lymph nodes boost cervical cancer treatment?

NCT ID NCT07653503

Recruiting now Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial explores whether injecting the immunotherapy drug nivolumab directly into lymph nodes before standard surgery is feasible and safe for people with cervical cancer. The study involves 12 participants and aims to see if this targeted approach can shrink tumors and improve surgical outcomes. If successful, it may pave the way for larger studies to confirm benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab
What this could lead to: If this approach works, it could offer a new way to treat cervical cancer by targeting the immune system directly at the lymph nodes, potentially improving surgical outcomes.
What could go wrong: This is a very early phase 1 trial with only 12 participants, so results may not apply broadly. The treatment could cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CARCINOMA

Contacts and locations

Locations

University Medical Centre Groningen
RECRUITING

Groningen, 9700 RB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.